secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001193125-22-145810
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Q1 Jelmyto revenue $13.6M (+81% YoY); net loss $28.4M; cash $137.1M
--------------------------------------------------------------------------

- Jelmyto net revenue $13.6M, +81% vs Q1 2021 ($7.5M).
- Net loss $28.4M ($1.25/shr) vs $25.9M ($1.17/shr) a year ago.
- Cash, cash equivalents & marketable securities $137.1M at Mar 31, up from $89.8M.
- Reiterated FY2022 Jelmyto revenue guidance $70-80M and operating expenses $140-160M.
- Phase 3 ENVISION trial of UGN-102 enrollment expected to complete by end 2022; NDA submission projected 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522145810/0001193125-22-145810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522145810/d261272d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-145810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer